Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

Nonviral CRISPR-based knock-in of chimeric antigen receptor transgenes into T cells for cell therapy

ET
60 Minutes

Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT technology.

Cas9-CLIPT (Cleaved, Linearized with Protein Template) is a groundbreaking technology designed to improve the efficiency of genome editing. It involves using a circular plasmid with a single target sequence for the Cas9 ribonucleoprotein (RNP). During manufacturing, the Cas9-RNP binds and cleaves the Nanoplasmid, linearizing the double-stranded DNA (dsDNA) in vitro. This linearized template, bound to Cas9-RNP, is then delivered to cells to promote precise knock-in via homology-directed repair. This method significantly enhances the precision and efficiency of CAR T cell production.

Key Takeaways:

  • Gain insights into cutting-edge genome editing technologies
  • Discover strategies to improve nonviral manufacturing processes
  • Learn practical applications and benefits of Cas9-CLIPT in CAR T cell manufacturing
  • And more

Speakers

Krishanu Saha

Krishanu Saha, PhD

Professor
University of Wisconsin-Madison

Krishanu Saha, PhD is a Professor and the Retina Research Foundation Kathryn and Latimer Murfee Chair at the University of Wisconsin-Madison. He leads pioneering research in nonviral genome editing methods for stem cells and somatic cells. Dr. Saha is also involved in large-scale collaborative projects, including the NSF Center for Cell Manufacturing Technologies and the NIH Somatic Cell Genome Editing Consortium. His work spans engineering, medicine, and ethics, contributing significantly to the field of therapeutic genome editing.

Max Sellman

Max Sellman

Senior Product Manager
Aldevron

Register here!

Already registered? Click here to login.
Date/Time:
ET